Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial

Celyad

today announced the completion of the 30-day safety follow-up of the first patient enrolled in  the second cohort in the Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM). Dr. Christian Homsy, CEO of Celyad, said: "The NKG2D CAR T-Cell Phase I trial is progressing well. No safety issue were reported since the beginning of the trial. We look forward to recruiting the next patients in this second dose cohort". Dr. Frédéric Lehmann, Head of Immuno-oncology at Celyad, added: "Our NKG2D CAR T-Cell Phase I study is advancing at a nice pace and according the